Hosted on MSN10mon
DCGI orders withdrawal of Olaparib for select cancer patients over safety concerns
AstraZeneca, which received approval for Olaparib in 2018 ... been directed to withdraw the said indication and revise the package insert" the DCGI said in a letter, which was reviewed by Mint.
MedPage Today10d
Pembrolizumab-Olaparib Boosts PFS in Non-BRCA Ovarian Cancer
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of ...